Expand all sections

Veligrotug

Extended indication Graves ophthalmopathy
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Veligrotug
Domain Chronic immune diseases
Reason of inclusion New medicine (specialité)
Main indication Eye disorders
Extended indication Graves ophthalmopathy
Manufacturer Viridian
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Insulin-like growth factor-I receptor antagonists Fabrikant: Viridian Therapeutics

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date September 2025
Expected Registration October 2026
Orphan drug Yes
Registration phase Clinical trials
Additional remarks De fabrikant verwacht een registratieaanvraag in te dienen in mei 2024

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

References Schildklier.nl
Additional remarks Ongeveer 75.000 mensen hebben de ziekte van Graves, 20% daarvan heeft de oogaandoening Graves ophthalmopathie. Ongeveer 5% loopt het risico de oogziekte in ernstige vorm te ontwikkelen (3.750)

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.